Study (LoE) | Population | Time for outcome (frequency of diagnosis) evaluation | Frequency of diagnosis (%) | |||||||
---|---|---|---|---|---|---|---|---|---|---|
RA | UA | CA | pSp | PsA | Connective tissue disease | ReA | Other | |||
Raza et al (2b)22 | EA <3 months (n=97) | 1 year | 25 | 41 | 7 | NR | 4 | NR | 6 | 9 |
van Gaalen et al (1b)23 | EA <2 years (n=467) | 1 year | 33 | 23 | 8 | 6 | 6 | 5 | 3 | 32 |
van Aken et al (1b)83 | EA <2 years (n=134) | 1 year | 35 | 2 | 1 | NR | 2 | 1 | 2 | 12 |
Ateş et al (1b)28 | EA <4 months (n=26) | 9 months | 19 | 27 | NR | 15 | NR | NR | 23 | 8 |
Binard et al (1b)84 | EA <1 year (n=220) | 30 months | 46 | 11 | 2 | 21 | NR | 5 | NR | 16 |
Bizzaro et al (1b)37 | EA <3 months (n=206) | 2 years | 38 | 30 | NR | NR | 6 | 4 | NR | 19 |
CA, crystal arthritis; EA, early arthritis; NR, not reported; PsA, psoriatic arthritis; pSp, peripheral spondyloarthritis; RA, rheumatoid arthritis; ReA, reactive arthritis; UA, undifferentiated arthritis.